Coronavirus | Bahrain approves Chinese COVID-19 vaccine for use

Over 7,700 signed up to take part in a trial of the Sinopharm vaccine in the kingdom

Published - December 13, 2020 05:05 pm IST - DUBAI

Bahrain said over 7,700 signed up to take part in a trial of the Sinopharm vaccine in the kingdom. Image used for representation purpose.

Bahrain said over 7,700 signed up to take part in a trial of the Sinopharm vaccine in the kingdom. Image used for representation purpose.

Bahrain said on Sunday it approved the use of a Chinese coronavirus vaccine, following its earlier approval of a vaccine made by Pfizer and its German partner BioNTech.

Separately, Kuwait has granted emergency use for the Pfizer vaccine.

Bahrain’s state-run news agency said the Sinopharm vaccine would be available in the island kingdom off the coast of Saudi Arabia in the Persian Gulf.

It offered few details though on study results of the vaccine, in line with the United Arab Emirates, which last week announced the vaccine was 86% effective. The Emirati statement provided few details but marked the first public release of information on the efficacy of the shot.

Bahrain said over 7,700 signed up to take part in a trial of the Sinopharm vaccine in the kingdom. The kingdom earlier said it plans to give the public free coronavirus vaccines, but has yet to answer any questions about its program.

The Sinopharm vaccine has been approved for emergency use in a few countries and the company is still conducting late-stage clinical trials in 10 countries. Morocco is gearing up for an ambitious COVID-19 vaccination program, aiming to vaccinate 80% of its adults in an operation starting this month that’s relying initially on the Sinopharm vaccine.

Sinopharm’s shot relies on a tested technology, using a killed virus to deliver the vaccine, similar to how polio immunizations are made. Leading Western competitors, like the shot made by Pfizer and its German partner BioNTech, use newer, less-proven technology to target the coronavirus’ spike protein using RNA. The United Kingdom already has begun vaccinating people with the Pfizer shot and the U.S. appears poised to shortly follow.

Already, Pfizer reports its shot as being 95% effective, while another RNA candidate from Moderna appears to be 94.5% effective. Results suggest a third vaccine from Oxford University and AstraZeneca is safe and about 70% effective, but questions remain about how well it may help protect those over 55.

On Sunday, Kuwait’s state-run KUNA news agency announced the oil-rich country’s Health Ministry had granted emergency use for the Pfizer vaccine. Already, the ministry had offered citizens the option to pre-register to receive the vaccine on its website.

0 / 0
Sign in to unlock member-only benefits!
  • Access 10 free stories every month
  • Save stories to read later
  • Access to comment on every story
  • Sign-up/manage your newsletter subscriptions with a single click
  • Get notified by email for early access to discounts & offers on our products
Sign in

Comments

Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.

We have migrated to a new commenting platform. If you are already a registered user of The Hindu and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.